DK175904B1 - Rekombinant avipoxvirus, viruset til anvendelse ved fremstilling af et lægemiddel til vertebrater og anvendelse af viruset ved fremstilling af et lægemiddel til behandling af pattedyr eller fugle for en infektion med et pattedyr- eller fuglepatogen - Google Patents
Rekombinant avipoxvirus, viruset til anvendelse ved fremstilling af et lægemiddel til vertebrater og anvendelse af viruset ved fremstilling af et lægemiddel til behandling af pattedyr eller fugle for en infektion med et pattedyr- eller fuglepatogen Download PDFInfo
- Publication number
- DK175904B1 DK175904B1 DK198902036A DK203689A DK175904B1 DK 175904 B1 DK175904 B1 DK 175904B1 DK 198902036 A DK198902036 A DK 198902036A DK 203689 A DK203689 A DK 203689A DK 175904 B1 DK175904 B1 DK 175904B1
- Authority
- DK
- Denmark
- Prior art keywords
- virus
- promoter
- gene
- vfp
- antigen
- Prior art date
Links
- 241000700605 Viruses Species 0.000 title claims description 185
- 241000700663 Avipoxvirus Species 0.000 title claims description 39
- 208000015181 infectious disease Diseases 0.000 title claims description 35
- 241000251539 Vertebrata <Metazoa> Species 0.000 title claims description 28
- 244000052769 pathogen Species 0.000 title claims description 27
- 230000001717 pathogenic effect Effects 0.000 title claims description 26
- 241000124008 Mammalia Species 0.000 title claims description 16
- 239000003814 drug Substances 0.000 title claims description 10
- 238000004519 manufacturing process Methods 0.000 title claims description 9
- 238000002360 preparation method Methods 0.000 title description 7
- 229940079593 drug Drugs 0.000 title description 4
- 108090000623 proteins and genes Proteins 0.000 claims description 130
- 206010037742 Rabies Diseases 0.000 claims description 79
- 239000000427 antigen Substances 0.000 claims description 57
- 102000036639 antigens Human genes 0.000 claims description 57
- 108091007433 antigens Proteins 0.000 claims description 57
- 206010046865 Vaccinia virus infection Diseases 0.000 claims description 45
- 208000007089 vaccinia Diseases 0.000 claims description 45
- 241000271566 Aves Species 0.000 claims description 43
- 230000014509 gene expression Effects 0.000 claims description 41
- 101710154606 Hemagglutinin Proteins 0.000 claims description 24
- 101710093908 Outer capsid protein VP4 Proteins 0.000 claims description 24
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 claims description 24
- 101710176177 Protein A56 Proteins 0.000 claims description 24
- 239000000185 hemagglutinin Substances 0.000 claims description 20
- 108010061100 Nucleoproteins Proteins 0.000 claims description 19
- 239000011159 matrix material Substances 0.000 claims description 18
- 241000711450 Infectious bronchitis virus Species 0.000 claims description 17
- 102000011931 Nucleoproteins Human genes 0.000 claims description 17
- 241000714266 Bovine leukemia virus Species 0.000 claims description 16
- 241000282326 Felis catus Species 0.000 claims description 13
- 241000711404 Avian avulavirus 1 Species 0.000 claims description 11
- 241000700584 Simplexvirus Species 0.000 claims description 10
- 230000002458 infectious effect Effects 0.000 claims description 9
- 241000712461 unidentified influenza virus Species 0.000 claims description 9
- 241000711798 Rabies lyssavirus Species 0.000 claims description 7
- 108020001507 fusion proteins Proteins 0.000 claims description 7
- 208000032839 leukemia Diseases 0.000 claims description 6
- 102000037865 fusion proteins Human genes 0.000 claims description 4
- 101000678879 Homo sapiens Atypical chemokine receptor 1 Proteins 0.000 claims description 3
- 208000002979 Influenza in Birds Diseases 0.000 claims description 3
- 241000713824 Rous-associated virus Species 0.000 claims description 3
- 206010064097 avian influenza Diseases 0.000 claims description 3
- 102100022717 Atypical chemokine receptor 1 Human genes 0.000 claims 1
- 239000013612 plasmid Substances 0.000 description 130
- 239000012634 fragment Substances 0.000 description 99
- 244000144977 poultry Species 0.000 description 88
- 235000013594 poultry meat Nutrition 0.000 description 87
- 210000004027 cell Anatomy 0.000 description 69
- 238000011081 inoculation Methods 0.000 description 61
- 108020004414 DNA Proteins 0.000 description 49
- 102000053602 DNA Human genes 0.000 description 49
- 241000287828 Gallus gallus Species 0.000 description 45
- 235000013330 chicken meat Nutrition 0.000 description 45
- 238000003780 insertion Methods 0.000 description 45
- 230000037431 insertion Effects 0.000 description 45
- 239000013598 vector Substances 0.000 description 44
- 241000700618 Vaccinia virus Species 0.000 description 40
- 241000283973 Oryctolagus cuniculus Species 0.000 description 33
- 230000006798 recombination Effects 0.000 description 33
- 108091034117 Oligonucleotide Proteins 0.000 description 31
- 238000010276 construction Methods 0.000 description 30
- 238000005215 recombination Methods 0.000 description 29
- 229960005486 vaccine Drugs 0.000 description 28
- 238000000034 method Methods 0.000 description 27
- 238000012360 testing method Methods 0.000 description 27
- 241001465754 Metazoa Species 0.000 description 26
- 210000002966 serum Anatomy 0.000 description 24
- 102000004169 proteins and genes Human genes 0.000 description 23
- 230000028993 immune response Effects 0.000 description 22
- 241000287219 Serinus canaria Species 0.000 description 19
- 108700004025 env Genes Proteins 0.000 description 18
- 101150030339 env gene Proteins 0.000 description 18
- 238000011144 upstream manufacturing Methods 0.000 description 18
- 108091026890 Coding region Proteins 0.000 description 17
- 102000004594 DNA Polymerase I Human genes 0.000 description 17
- 108010017826 DNA Polymerase I Proteins 0.000 description 17
- 230000015572 biosynthetic process Effects 0.000 description 17
- 108090000288 Glycoproteins Proteins 0.000 description 16
- 239000000047 product Substances 0.000 description 16
- 230000004044 response Effects 0.000 description 16
- 241000283690 Bos taurus Species 0.000 description 15
- 101150082239 G gene Proteins 0.000 description 15
- 102000003886 Glycoproteins Human genes 0.000 description 15
- 238000002255 vaccination Methods 0.000 description 15
- 241000699670 Mus sp. Species 0.000 description 14
- 238000000338 in vitro Methods 0.000 description 14
- 230000003902 lesion Effects 0.000 description 14
- 239000002773 nucleotide Substances 0.000 description 14
- 125000003729 nucleotide group Chemical group 0.000 description 14
- 241000894007 species Species 0.000 description 14
- 238000003556 assay Methods 0.000 description 13
- 238000002474 experimental method Methods 0.000 description 13
- 239000007857 degradation product Substances 0.000 description 12
- 238000010790 dilution Methods 0.000 description 12
- 239000012895 dilution Substances 0.000 description 12
- 230000036961 partial effect Effects 0.000 description 12
- 102000005936 beta-Galactosidase Human genes 0.000 description 11
- 108010005774 beta-Galactosidase Proteins 0.000 description 11
- 239000002299 complementary DNA Substances 0.000 description 11
- 230000002068 genetic effect Effects 0.000 description 11
- 239000006166 lysate Substances 0.000 description 11
- 238000007918 intramuscular administration Methods 0.000 description 10
- 239000000523 sample Substances 0.000 description 10
- 241000588724 Escherichia coli Species 0.000 description 9
- 108700026244 Open Reading Frames Proteins 0.000 description 9
- 241000714233 Rous-associated virus type 1 Species 0.000 description 9
- 230000000890 antigenic effect Effects 0.000 description 9
- 210000004369 blood Anatomy 0.000 description 9
- 239000008280 blood Substances 0.000 description 9
- 230000015556 catabolic process Effects 0.000 description 9
- 238000006731 degradation reaction Methods 0.000 description 9
- 238000003018 immunoassay Methods 0.000 description 9
- 229920002477 rna polymer Polymers 0.000 description 9
- 101150069452 z gene Proteins 0.000 description 9
- 108091028043 Nucleic acid sequence Proteins 0.000 description 8
- 238000009396 hybridization Methods 0.000 description 8
- 238000001114 immunoprecipitation Methods 0.000 description 8
- 206010022000 influenza Diseases 0.000 description 8
- 210000004962 mammalian cell Anatomy 0.000 description 8
- 210000001519 tissue Anatomy 0.000 description 8
- 238000002965 ELISA Methods 0.000 description 7
- 108091081024 Start codon Proteins 0.000 description 7
- 230000036039 immunity Effects 0.000 description 7
- 238000013518 transcription Methods 0.000 description 7
- 230000035897 transcription Effects 0.000 description 7
- 238000012546 transfer Methods 0.000 description 7
- 230000003612 virological effect Effects 0.000 description 7
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 6
- 230000003053 immunization Effects 0.000 description 6
- 239000002054 inoculum Substances 0.000 description 6
- 230000010076 replication Effects 0.000 description 6
- 230000000405 serological effect Effects 0.000 description 6
- 238000013519 translation Methods 0.000 description 6
- 230000003442 weekly effect Effects 0.000 description 6
- 241000282472 Canis lupus familiaris Species 0.000 description 5
- 238000012286 ELISA Assay Methods 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 238000010367 cloning Methods 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 235000013601 eggs Nutrition 0.000 description 5
- 239000000499 gel Substances 0.000 description 5
- 238000002649 immunization Methods 0.000 description 5
- 238000000099 in vitro assay Methods 0.000 description 5
- 230000001939 inductive effect Effects 0.000 description 5
- 229920001184 polypeptide Polymers 0.000 description 5
- 108090000765 processed proteins & peptides Proteins 0.000 description 5
- 102000004196 processed proteins & peptides Human genes 0.000 description 5
- 230000014621 translational initiation Effects 0.000 description 5
- 108020004705 Codon Proteins 0.000 description 4
- 108010054576 Deoxyribonuclease EcoRI Proteins 0.000 description 4
- 208000000666 Fowlpox Diseases 0.000 description 4
- 102000002464 Galactosidases Human genes 0.000 description 4
- 108010093031 Galactosidases Proteins 0.000 description 4
- 241000238631 Hexapoda Species 0.000 description 4
- 241000286209 Phasianidae Species 0.000 description 4
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 4
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 4
- 238000004113 cell culture Methods 0.000 description 4
- 238000005520 cutting process Methods 0.000 description 4
- 230000001506 immunosuppresive effect Effects 0.000 description 4
- 230000000977 initiatory effect Effects 0.000 description 4
- 239000003550 marker Substances 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 238000006386 neutralization reaction Methods 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 108091008146 restriction endonucleases Proteins 0.000 description 4
- 239000002356 single layer Substances 0.000 description 4
- 238000006467 substitution reaction Methods 0.000 description 4
- 238000004448 titration Methods 0.000 description 4
- 238000001890 transfection Methods 0.000 description 4
- OPIFSICVWOWJMJ-AEOCFKNESA-N 5-bromo-4-chloro-3-indolyl beta-D-galactoside Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=CNC2=CC=C(Br)C(Cl)=C12 OPIFSICVWOWJMJ-AEOCFKNESA-N 0.000 description 3
- 241001135961 Amsacta moorei entomopoxvirus Species 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- 101100333573 Bovine leukemia virus env gene Proteins 0.000 description 3
- 241000178270 Canarypox virus Species 0.000 description 3
- 230000004543 DNA replication Effects 0.000 description 3
- 201000004624 Dermatitis Diseases 0.000 description 3
- 101150039660 HA gene Proteins 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 241001494479 Pecora Species 0.000 description 3
- 238000012300 Sequence Analysis Methods 0.000 description 3
- 230000003321 amplification Effects 0.000 description 3
- 208000010668 atopic eczema Diseases 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000005540 biological transmission Effects 0.000 description 3
- 239000013592 cell lysate Substances 0.000 description 3
- 230000000120 cytopathologic effect Effects 0.000 description 3
- 230000034994 death Effects 0.000 description 3
- 231100000517 death Toxicity 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000012091 fetal bovine serum Substances 0.000 description 3
- 230000001605 fetal effect Effects 0.000 description 3
- 210000002950 fibroblast Anatomy 0.000 description 3
- 238000007710 freezing Methods 0.000 description 3
- 230000008014 freezing Effects 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 101150036031 gD gene Proteins 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 230000012447 hatching Effects 0.000 description 3
- 238000010166 immunofluorescence Methods 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 238000011065 in-situ storage Methods 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 238000013507 mapping Methods 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 238000003199 nucleic acid amplification method Methods 0.000 description 3
- 210000002729 polyribosome Anatomy 0.000 description 3
- 239000002243 precursor Substances 0.000 description 3
- 230000001681 protective effect Effects 0.000 description 3
- 101150116497 sacm1l gene Proteins 0.000 description 3
- 238000010186 staining Methods 0.000 description 3
- 238000007920 subcutaneous administration Methods 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 238000010257 thawing Methods 0.000 description 3
- 241000700570 unidentified entomopoxvirus Species 0.000 description 3
- JTTIOYHBNXDJOD-UHFFFAOYSA-N 2,4,6-triaminopyrimidine Chemical compound NC1=CC(N)=NC(N)=N1 JTTIOYHBNXDJOD-UHFFFAOYSA-N 0.000 description 2
- 101150110188 30 gene Proteins 0.000 description 2
- 208000030507 AIDS Diseases 0.000 description 2
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 2
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- 241000282693 Cercopithecidae Species 0.000 description 2
- 206010011703 Cyanosis Diseases 0.000 description 2
- 102100027723 Endogenous retrovirus group K member 6 Rec protein Human genes 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 108091029865 Exogenous DNA Proteins 0.000 description 2
- 101150057091 FP1 gene Proteins 0.000 description 2
- 241000700721 Hepatitis B virus Species 0.000 description 2
- 101000724418 Homo sapiens Neutral amino acid transporter B(0) Proteins 0.000 description 2
- 241000255777 Lepidoptera Species 0.000 description 2
- 241000721703 Lymantria dispar Species 0.000 description 2
- 101150118742 NP gene Proteins 0.000 description 2
- 102100028267 Neutral amino acid transporter B(0) Human genes 0.000 description 2
- 206010033799 Paralysis Diseases 0.000 description 2
- 101710182846 Polyhedrin Proteins 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 108020004511 Recombinant DNA Proteins 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 101150003725 TK gene Proteins 0.000 description 2
- 108091023040 Transcription factor Proteins 0.000 description 2
- 102000040945 Transcription factor Human genes 0.000 description 2
- 241000700647 Variola virus Species 0.000 description 2
- 208000036142 Viral infection Diseases 0.000 description 2
- 206010052428 Wound Diseases 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- VEZXCJBBBCKRPI-UHFFFAOYSA-N beta-propiolactone Chemical compound O=C1CCO1 VEZXCJBBBCKRPI-UHFFFAOYSA-N 0.000 description 2
- 239000004927 clay Substances 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 235000021186 dishes Nutrition 0.000 description 2
- 210000002257 embryonic structure Anatomy 0.000 description 2
- 210000003754 fetus Anatomy 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 230000035931 haemagglutination Effects 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 230000005847 immunogenicity Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 238000011005 laboratory method Methods 0.000 description 2
- 210000002414 leg Anatomy 0.000 description 2
- 238000002703 mutagenesis Methods 0.000 description 2
- 231100000350 mutagenesis Toxicity 0.000 description 2
- 230000003472 neutralizing effect Effects 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 229920002401 polyacrylamide Polymers 0.000 description 2
- 229940024231 poxvirus vaccine Drugs 0.000 description 2
- 229960000380 propiolactone Drugs 0.000 description 2
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 210000001995 reticulocyte Anatomy 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 210000003437 trachea Anatomy 0.000 description 2
- 230000002103 transcriptional effect Effects 0.000 description 2
- 230000009385 viral infection Effects 0.000 description 2
- 239000007762 w/o emulsion Substances 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- QFVHZQCOUORWEI-UHFFFAOYSA-N 4-[(4-anilino-5-sulfonaphthalen-1-yl)diazenyl]-5-hydroxynaphthalene-2,7-disulfonic acid Chemical compound C=12C(O)=CC(S(O)(=O)=O)=CC2=CC(S(O)(=O)=O)=CC=1N=NC(C1=CC=CC(=C11)S(O)(=O)=O)=CC=C1NC1=CC=CC=C1 QFVHZQCOUORWEI-UHFFFAOYSA-N 0.000 description 1
- 235000006576 Althaea officinalis Nutrition 0.000 description 1
- 241000670670 Amsacta Species 0.000 description 1
- 102100034613 Annexin A2 Human genes 0.000 description 1
- 108090000668 Annexin A2 Proteins 0.000 description 1
- IJYZHIOOBGIINM-WDSKDSINSA-N Arg-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@@H](N)CCCN=C(N)N IJYZHIOOBGIINM-WDSKDSINSA-N 0.000 description 1
- 241000238017 Astacoidea Species 0.000 description 1
- 241001367049 Autographa Species 0.000 description 1
- 101150042514 B1 gene Proteins 0.000 description 1
- 101000583086 Bunodosoma granuliferum Delta-actitoxin-Bgr2b Proteins 0.000 description 1
- 102100021935 C-C motif chemokine 26 Human genes 0.000 description 1
- 108020004638 Circular DNA Proteins 0.000 description 1
- 241000254173 Coleoptera Species 0.000 description 1
- 229920001076 Cutan Polymers 0.000 description 1
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 241000701832 Enterobacteria phage T3 Species 0.000 description 1
- 241000700572 Entomopoxvirinae Species 0.000 description 1
- 101710121417 Envelope glycoprotein Proteins 0.000 description 1
- 101710091045 Envelope protein Proteins 0.000 description 1
- 101001090612 Escherichia phage Mu Protease I Proteins 0.000 description 1
- 206010069540 Generalised vaccinia Diseases 0.000 description 1
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 108060003393 Granulin Proteins 0.000 description 1
- 101000897493 Homo sapiens C-C motif chemokine 26 Proteins 0.000 description 1
- 101001002657 Homo sapiens Interleukin-2 Proteins 0.000 description 1
- 241000700588 Human alphaherpesvirus 1 Species 0.000 description 1
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- 208000036747 Infectious transmissions Diseases 0.000 description 1
- 241000122235 Junco hyemalis Species 0.000 description 1
- HHSJMSCOLJVTCX-ZDLURKLDSA-N L-Glutaminyl-L-threonine Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@@H](N)CCC(N)=O HHSJMSCOLJVTCX-ZDLURKLDSA-N 0.000 description 1
- 125000003798 L-tyrosyl group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C([H])([H])C1=C([H])C([H])=C(O[H])C([H])=C1[H] 0.000 description 1
- 241001214257 Mene Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- JLNMSNDDYBZCIB-UHFFFAOYSA-N OOOOS Chemical compound OOOOS JLNMSNDDYBZCIB-UHFFFAOYSA-N 0.000 description 1
- 241000238814 Orthoptera Species 0.000 description 1
- 241000209094 Oryza Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 241000287127 Passeridae Species 0.000 description 1
- 208000027954 Poultry disease Diseases 0.000 description 1
- 229940124939 Pox vaccine Drugs 0.000 description 1
- 229940096437 Protein S Drugs 0.000 description 1
- 101710188315 Protein X Proteins 0.000 description 1
- 206010037888 Rash pustular Diseases 0.000 description 1
- 101100173636 Rattus norvegicus Fhl2 gene Proteins 0.000 description 1
- 241000287231 Serinus Species 0.000 description 1
- 238000002105 Southern blotting Methods 0.000 description 1
- 101710198474 Spike protein Proteins 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 101800001271 Surface protein Proteins 0.000 description 1
- 108010008038 Synthetic Vaccines Proteins 0.000 description 1
- 108700005077 Viral Genes Proteins 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 230000005875 antibody response Effects 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 239000012267 brine Substances 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 101150055766 cat gene Proteins 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 239000013553 cell monolayer Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 239000003593 chromogenic compound Substances 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000001723 curing Methods 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 206010014599 encephalitis Diseases 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000008029 eradication Effects 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 238000001215 fluorescent labelling Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000000087 hemolymph Anatomy 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 108010077284 hepatitis B surface antigen presurface protein 2 Proteins 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000007901 in situ hybridization Methods 0.000 description 1
- 229940031551 inactivated vaccine Drugs 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 229960003971 influenza vaccine Drugs 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000013101 initial test Methods 0.000 description 1
- 239000003999 initiator Substances 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- RQIDGZHMTWSMMC-TZNPKLQUSA-N juvenile hormone I Chemical compound COC(=O)/C=C(C)/CC\C=C(/CC)CC[C@H]1O[C@@]1(C)CC RQIDGZHMTWSMMC-TZNPKLQUSA-N 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 210000005265 lung cell Anatomy 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000004237 neck muscle Anatomy 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- 238000007899 nucleic acid hybridization Methods 0.000 description 1
- 229940126578 oral vaccine Drugs 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 210000004681 ovum Anatomy 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 238000012809 post-inoculation Methods 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000012716 precipitator Substances 0.000 description 1
- 208000029561 pustule Diseases 0.000 description 1
- 238000000163 radioactive labelling Methods 0.000 description 1
- 229940124551 recombinant vaccine Drugs 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012770 revaccination Methods 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 235000021462 rice dishes Nutrition 0.000 description 1
- 210000003079 salivary gland Anatomy 0.000 description 1
- 238000007790 scraping Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 239000010865 sewage Substances 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- 235000015096 spirit Nutrition 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 210000000966 temporal muscle Anatomy 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000010474 transient expression Effects 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 239000003656 tris buffered saline Substances 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 230000029812 viral genome replication Effects 0.000 description 1
- 230000017613 viral reproduction Effects 0.000 description 1
- 230000006490 viral transcription Effects 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
- 239000005723 virus inoculator Substances 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 230000003313 weakening effect Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
- C12N2710/16622—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24041—Use of virus, viral particle or viral elements as a vector
- C12N2710/24043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
- C12N2740/15022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
- C12N2760/18122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/20011—Rhabdoviridae
- C12N2760/20111—Lyssavirus, e.g. rabies virus
- C12N2760/20122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Communicable Diseases (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Hematology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DK200500158A DK175980B1 (da) | 1987-08-28 | 2005-02-02 | Recombinante vacciniavira og anvendelsen af samme |
Applications Claiming Priority (10)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US9071187A | 1987-08-28 | 1987-08-28 | |
| US9071187 | 1987-08-28 | ||
| US11033587A | 1987-10-20 | 1987-10-20 | |
| US11033587 | 1987-10-20 | ||
| US18605488A | 1988-04-25 | 1988-04-25 | |
| US18605488 | 1988-04-25 | ||
| US23439088A | 1988-08-23 | 1988-08-23 | |
| US23439088 | 1988-08-23 | ||
| PCT/US1988/002816 WO1989003429A1 (en) | 1987-08-28 | 1988-08-24 | Recombinant avipox virus |
| US8802816 | 1988-08-24 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| DK203689D0 DK203689D0 (da) | 1989-04-27 |
| DK203689A DK203689A (da) | 1989-06-27 |
| DK175904B1 true DK175904B1 (da) | 2005-06-06 |
Family
ID=27492413
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK198902036A DK175904B1 (da) | 1987-08-28 | 1989-04-27 | Rekombinant avipoxvirus, viruset til anvendelse ved fremstilling af et lægemiddel til vertebrater og anvendelse af viruset ved fremstilling af et lægemiddel til behandling af pattedyr eller fugle for en infektion med et pattedyr- eller fuglepatogen |
Country Status (17)
| Country | Link |
|---|---|
| JP (3) | JP3348156B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR970011149B1 (cg-RX-API-DMAC7.html) |
| AR (1) | AR241939A1 (cg-RX-API-DMAC7.html) |
| AT (1) | AT408549B (cg-RX-API-DMAC7.html) |
| AU (2) | AU2427588A (cg-RX-API-DMAC7.html) |
| BE (1) | BE1002134A5 (cg-RX-API-DMAC7.html) |
| CH (2) | CH679933A5 (cg-RX-API-DMAC7.html) |
| DE (4) | DE10399032I1 (cg-RX-API-DMAC7.html) |
| DK (1) | DK175904B1 (cg-RX-API-DMAC7.html) |
| FR (1) | FR2621487B1 (cg-RX-API-DMAC7.html) |
| GB (1) | GB2217718B (cg-RX-API-DMAC7.html) |
| IL (1) | IL87581A0 (cg-RX-API-DMAC7.html) |
| IT (1) | IT1229484B (cg-RX-API-DMAC7.html) |
| LU (2) | LU90951I2 (cg-RX-API-DMAC7.html) |
| NL (4) | NL195051C (cg-RX-API-DMAC7.html) |
| NZ (1) | NZ225970A (cg-RX-API-DMAC7.html) |
| WO (1) | WO1989003429A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (121)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5338683A (en) * | 1981-12-24 | 1994-08-16 | Health Research Incorporated | Vaccinia virus containing DNA sequences encoding herpesvirus glycoproteins |
| US5505941A (en) * | 1981-12-24 | 1996-04-09 | Health Research, Inc. | Recombinant avipox virus and method to induce an immune response |
| US7045313B1 (en) | 1982-11-30 | 2006-05-16 | The United States Of America As Represented By The Department Of Health And Human Services | Recombinant vaccinia virus containing a chimeric gene having foreign DNA flanked by vaccinia regulatory DNA |
| DE10399032I1 (de) * | 1987-08-28 | 2004-01-29 | Health Research Inc | Rekombinante Viren. |
| US5286639A (en) * | 1987-09-16 | 1994-02-15 | Nippon Zeon Co., Ltd. | Recombinant avipoxvirus |
| DE3813093A1 (de) * | 1988-04-19 | 1989-11-09 | Immuno Ag | Rekombinantes plasmid, verfahren zum herstellen eines rekombinanten avipoxvirus, rekombinantes avipoxvirus und dessen verwendung |
| US5631154A (en) * | 1988-06-10 | 1997-05-20 | Therion Biologics, Incorporated | Self assembled, defective, non-self-propagating lentivirus particles |
| US5310671A (en) * | 1988-06-24 | 1994-05-10 | British Technology Group Limited | Fowlpox virus non-essential regions |
| US5093258A (en) * | 1988-08-26 | 1992-03-03 | Therion Biologics Corporation | Recombinant fowlpox virus and recombination vector |
| CA2001001A1 (en) * | 1988-10-21 | 1990-04-21 | Matthew M. Binns | Fowlpox virus promoter |
| US6248333B1 (en) | 1990-04-04 | 2001-06-19 | Health Research Inc. | Isolated nucleic acid sequence of equine herpesvirus type 1 glycoprotein D (EHV-1 gD) |
| US5204243A (en) * | 1990-02-14 | 1993-04-20 | Health Research Incorporated | Recombinant poxvirus internal cores |
| US5514375A (en) * | 1990-08-15 | 1996-05-07 | Virogenetics Corporation | Flavivirus recombinant poxvirus vaccine |
| MY109299A (en) * | 1990-08-15 | 1996-12-31 | Virogenetics Corp | Recombinant pox virus encoding flaviviral structural proteins |
| FR2668064B1 (fr) | 1990-10-23 | 1994-12-16 | Transgene Sa | Composition pharmaceutique pour le traitement ou la prevention d'une tumeur maligne. |
| US5756102A (en) * | 1990-11-20 | 1998-05-26 | Virogenetics Corporation | Poxvirus-canine distemper virus (CDV) recombinants and compositions and methods employing the recombinants |
| IE71643B1 (en) * | 1990-11-20 | 1997-02-26 | Virogenetics Corp | A recombinant poxviral vaccine for canine distemper |
| US5759841A (en) * | 1990-11-20 | 1998-06-02 | Virogenetics Corporation | Immunological composition of measles virus utilizing recombinant poxvirus |
| US6309647B1 (en) | 1999-07-15 | 2001-10-30 | Aventis Pasteur | Poxvirus—canine dispemper virus (CDV) or measles virus recombinants and compositions and methods employing the recombinants |
| US5503834A (en) * | 1990-11-20 | 1996-04-02 | Virogenetics Corporation | Measles virus recombinant poxvirus vaccine |
| US5338679A (en) * | 1991-01-08 | 1994-08-16 | Her Majesty The Queen In Right Of Canada, As Represented By National Research Council Canada And Forestry Canada | Vertebrate poxvoris expression vector under the control of entomopoxvirus spheroidin gene promoter |
| US5766598A (en) * | 1991-03-07 | 1998-06-16 | Virogenetics Corporation | Recombinant attenuated ALVAC canarypoxvirus expression vectors containing heterologous DNA segments encoding lentiviral gene products |
| US5766597A (en) * | 1991-03-07 | 1998-06-16 | Virogenetics Corporation | Malaria recombinant poxviruses |
| US5756101A (en) * | 1991-07-01 | 1998-05-26 | Pasteur Merieux Serums Et Vaccins | Malaria recombinant poxvirus |
| JP3602530B2 (ja) * | 1991-03-07 | 2004-12-15 | ヴァイロジェネティクス コーポレイション | 遺伝子操作したワクチン菌株 |
| US5863542A (en) * | 1991-03-07 | 1999-01-26 | Virogenetics Corporation | Recombinant attenuated ALVAC canaryopox virus containing heterologous HIV or SIV inserts |
| WO1992016616A1 (en) * | 1991-03-20 | 1992-10-01 | Virogenetics Corporation | Malaria recombinant poxvirus vaccine |
| JP3504659B2 (ja) * | 1991-06-14 | 2004-03-08 | ヴァイロジェネティクス コーポレイション | 免疫不全ウイルス組換えポックスウイルスワクチン |
| JPH06509235A (ja) * | 1991-07-26 | 1994-10-20 | ヴァイロジェネティクス コーポレイション | 伝染性ファブリキウス嚢病ウイルス組換えポックスウイルスワクチン |
| DE69133333T2 (de) * | 1991-08-26 | 2004-07-29 | Baxter Healthcare S.A. | Ein intaktes FPV-tk-Gen enthaltender rekombinanter Virus der Vogelpocken |
| US5443831A (en) * | 1991-10-29 | 1995-08-22 | University Of Delaware | Gene encoding glycoprotein B of Infectious Laryngotracheitis Virus |
| US6033904A (en) * | 1992-01-13 | 2000-03-07 | Syntro Corporation | Recombinant swinepox virus |
| US5869312A (en) * | 1992-01-13 | 1999-02-09 | Syntro Corporation | Recombinant swinepox virus |
| US6497882B1 (en) | 1992-01-13 | 2002-12-24 | Syntro Corporation | Recombinant swinepox virus |
| US6251403B1 (en) | 1992-01-13 | 2001-06-26 | Syntro Corporation | Recombinant swinepox virus |
| EP1489165A1 (en) * | 1992-01-13 | 2004-12-22 | Virogenetics Corporation | Recombinant fowlpox vaccine for protection against marek's disease |
| US6127163A (en) * | 1992-01-13 | 2000-10-03 | Syntro Corporation | Recombinant swinepox virus |
| US6328975B1 (en) | 1992-01-13 | 2001-12-11 | Syntro Corporation | Recombinant swinepox virus |
| EP0662139A1 (en) * | 1992-09-21 | 1995-07-12 | Chiron Corporation | Recombinant retroviral vector against felv and/or fiv |
| WO1994019014A1 (en) * | 1993-02-26 | 1994-09-01 | Syntro Corporation | Recombinant fowlpox virus s-fpv-043 and uses thereof |
| AU727278B2 (en) * | 1993-02-26 | 2000-12-07 | Syntro Corporation | Recombinant fowlpox viruses and uses thereof II |
| US5925358A (en) * | 1993-02-26 | 1999-07-20 | Syntro Corporation | Recombinant fowlpox viruses and uses thereof |
| US6136318A (en) * | 1993-02-26 | 2000-10-24 | Cochran; Mark D. | Recombinant fowlpox viruses and uses thereof |
| US5496731A (en) * | 1993-03-25 | 1996-03-05 | Xu; Hong-Ji | Broad-spectrum tumor suppressor genes, gene products and methods for tumor suppressor gene therapy |
| US5843742A (en) * | 1994-12-16 | 1998-12-01 | Avigen Incorporated | Adeno-associated derived vector systems for gene delivery and integration into target cells |
| EP0753581A1 (en) | 1995-07-10 | 1997-01-15 | Immuno Ag | Improved recombinant eukaryotic cytoplasmic viruses, method for their production and their use as vaccines |
| US5858373A (en) * | 1995-12-01 | 1999-01-12 | Virogenetics Corporation | Recombinant poxvirus-feline infectious peritionitis virus, compositions thereof and methods for making and using them |
| WO1998004727A1 (en) | 1996-07-25 | 1998-02-05 | Therion Biologics Corporation | Recombinant pox virus for immunization against tumor-associated antigens |
| US6106825A (en) * | 1997-05-07 | 2000-08-22 | University Of Florida | Entomopoxvirus-vertebrate gene delivery vector and method |
| AU3910097A (en) * | 1997-08-05 | 1999-03-01 | Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The | Live recombinant vaccine comprising inefficiently or non-replicating vir us |
| US6248582B1 (en) * | 1997-10-08 | 2001-06-19 | Imran Khan | Gene deleted recombinant FeLV proviral DNA for production of vaccines against FeLV |
| JPH11165762A (ja) | 1997-12-01 | 1999-06-22 | Lintec Corp | チップ体搬送用カバーテープおよび封止構造体 |
| US20020147143A1 (en) | 1998-03-18 | 2002-10-10 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of lung cancer |
| US20030235557A1 (en) | 1998-09-30 | 2003-12-25 | Corixa Corporation | Compositions and methods for WT1 specific immunotherapy |
| US6221349B1 (en) | 1998-10-20 | 2001-04-24 | Avigen, Inc. | Adeno-associated vectors for expression of factor VIII by target cells |
| US6200560B1 (en) | 1998-10-20 | 2001-03-13 | Avigen, Inc. | Adeno-associated virus vectors for expression of factor VIII by target cells |
| JP2002533124A (ja) | 1998-12-31 | 2002-10-08 | カイロン コーポレイション | Ｈｉｖポリペプチドの改善された発現およびウイルス様粒子の生成 |
| US7935805B1 (en) | 1998-12-31 | 2011-05-03 | Novartis Vaccines & Diagnostics, Inc | Polynucleotides encoding antigenic HIV Type C polypeptides, polypeptides and uses thereof |
| JP5138851B2 (ja) | 1999-06-28 | 2013-02-06 | オクラホマ メディカル リサーチ ファウンデーション | 触媒的に活性な組換えメマプシンおよびその使用方法 |
| MXPA02008279A (es) | 2000-02-23 | 2002-11-29 | Smithkline Beecham Biolog | Proteinas animales especificas de tumor. |
| JP2004513615A (ja) | 2000-06-28 | 2004-05-13 | コリクサ コーポレイション | 肺癌の治療および診断のための組成物および方法 |
| JP2005502591A (ja) | 2001-01-12 | 2005-01-27 | カイロン コーポレイション | 核酸粘膜免疫 |
| US6942864B2 (en) * | 2001-03-08 | 2005-09-13 | Akzo Nobel N.V. | Leporipox-based vector vaccines |
| JP4499311B2 (ja) * | 2001-04-27 | 2010-07-07 | シャープ株式会社 | 放送受信端末 |
| CA2446788A1 (en) | 2001-05-09 | 2002-11-14 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of prostate cancer |
| CA2452119C (en) | 2001-07-05 | 2013-10-15 | Chiron Corporation | Polynucleotides encoding antigenic hiv type b and/or type c polypeptides, polypeptides and uses thereof |
| AU2002320314A1 (en) | 2001-07-05 | 2003-01-21 | Chiron, Corporation | Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof |
| AU2002365279B2 (en) | 2001-12-17 | 2009-08-13 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of inflammatory bowel disease |
| US7960522B2 (en) | 2003-01-06 | 2011-06-14 | Corixa Corporation | Certain aminoalkyl glucosaminide phosphate compounds and their use |
| EP2940028B8 (en) | 2003-01-06 | 2017-09-27 | Corixa Corporation | Certain aminoalkyl glucosaminide phosphate compounds and their use |
| EP1628680B1 (en) | 2003-05-15 | 2012-10-24 | Novartis Vaccines and Diagnostics, Inc. | Hiv polynucleotides and polypeptides derived from botswana mj4 |
| US7261882B2 (en) | 2003-06-23 | 2007-08-28 | Reagents Of The University Of Colorado | Methods for treating neuropathic pain by administering IL-10 polypeptides |
| EP2893938B1 (en) | 2004-09-22 | 2019-03-06 | GlaxoSmithKline Biologicals SA | Immunogenic composition for use in vaccination against Staphylococcei |
| JP5215865B2 (ja) | 2005-11-22 | 2013-06-19 | ノバルティス ヴァクシンズ アンド ダイアグノスティクス インコーポレイテッド | ノロウイルス抗原およびサポウイルス抗原 |
| EP1979488A4 (en) | 2006-01-09 | 2009-05-27 | Univ California | IMMUNOSTIMULATING COMBINATIONS OF TNFRSF, TLR, NLR, RHR, PURINERIC RECEPTOR, AND CYTOKIN RECEPTOR ANTONISTS FOR VACCINES AND TUMOR IMMUNOTHERAPY |
| EP2441469A1 (en) | 2006-03-14 | 2012-04-18 | Oregon Health and Science University | Methods for producing an immune response to tuberculosis |
| US8188214B2 (en) | 2007-02-28 | 2012-05-29 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Brachyury polypeptides and methods for use |
| WO2009049350A1 (en) | 2007-10-15 | 2009-04-23 | The University Of Queensland | Expression system for modulating an immune response |
| US8691502B2 (en) | 2008-10-31 | 2014-04-08 | Tremrx, Inc. | T-cell vaccination with viral vectors via mechanical epidermal disruption |
| BRPI1005670A8 (pt) | 2009-01-05 | 2017-12-26 | Epitogenesis Inc | composições adjuvantes e processos de uso. |
| US8664183B2 (en) | 2009-02-27 | 2014-03-04 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | SPANX-B polypeptides and their use |
| EP3360566B1 (en) | 2009-11-20 | 2019-12-25 | Oregon Health&Science University | Methods for detecting a mycobacterium tuberculosis infection |
| US20130052221A1 (en) | 2010-02-26 | 2013-02-28 | The Govt. of the U.S, as represented by The Sec. of The Dept. of Health and Human Services | Dna-protein vaccination protocols |
| US9795658B2 (en) | 2010-04-20 | 2017-10-24 | Admedus Vaccines Pty Ltd | Expression system for modulating an immune response |
| WO2012106281A2 (en) | 2011-01-31 | 2012-08-09 | The General Hospital Corporation | Multimodal trail molecules and uses in cellular therapies |
| WO2012151272A2 (en) | 2011-05-02 | 2012-11-08 | Tremrx, Inc. | T-cell vaccination with viral vectors via mechanical epidermal disruption |
| WO2012177595A1 (en) | 2011-06-21 | 2012-12-27 | Oncofactor Corporation | Compositions and methods for the therapy and diagnosis of cancer |
| US10561720B2 (en) | 2011-06-24 | 2020-02-18 | EpitoGenesis, Inc. | Pharmaceutical compositions, comprising a combination of select carriers, vitamins, tannins and flavonoids as antigen-specific immuno-modulators |
| WO2013082106A1 (en) | 2011-12-02 | 2013-06-06 | The General Hospital Corporation | Differentiation into brown adipocytes |
| US9605074B2 (en) | 2012-08-30 | 2017-03-28 | The General Hospital Corporation | Multifunctional nanobodies for treating cancer |
| WO2014043535A1 (en) | 2012-09-14 | 2014-03-20 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Compositions for the treatment of cancer |
| WO2014043518A1 (en) | 2012-09-14 | 2014-03-20 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Brachyury protein, non-poxvirus non-yeast vectors encoding brachyury protein, and their use |
| WO2014172560A1 (en) | 2013-04-17 | 2014-10-23 | Genzyme Corporation | Compositions and methods for treating and preventing macular degeneration |
| JP6649250B2 (ja) | 2013-05-21 | 2020-02-19 | プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ | 操作されたヘム結合性構成物およびその使用 |
| CA2930693A1 (en) | 2013-11-15 | 2015-05-21 | The Board Of Trustees Of The Leland Stanford Junior Unversity | Methods of treating heart failure with agonists of hypocretin receptor 2 |
| CN111068072A (zh) | 2014-02-06 | 2020-04-28 | 建新公司 | 用于治疗和预防黄斑变性的组合物及方法 |
| WO2016044707A1 (en) | 2014-09-18 | 2016-03-24 | Cedars-Sinai Medical Center | Compositions and methods for treating fibrosis |
| US20180071380A1 (en) | 2015-03-20 | 2018-03-15 | The Regents Of The University Of Michigan | Immunogenic compositions for use in vaccination against bordetella |
| WO2016168601A1 (en) | 2015-04-17 | 2016-10-20 | Khalid Shah | Agents, systems and methods for treating cancer |
| CN114366802A (zh) | 2015-04-22 | 2022-04-19 | 西达-赛奈医疗中心 | 用于治疗2型糖尿病的肠内递送的苦味寡肽 |
| ES2959642T3 (es) | 2015-05-13 | 2024-02-27 | The Us Secretary Of The Department Of Health And Human Services | Metodos y composiciones para inducir una respuesta inmunitaria mediante construcciones con elementos conservados |
| WO2016196366A1 (en) | 2015-05-29 | 2016-12-08 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Extension of replicative lifespan in diseases of premature aging using p53 isoforms |
| EP3313863B1 (en) | 2015-06-29 | 2020-12-23 | The Board of Trustees of the Leland Stanford Junior University | Degron fusion constructs and methods for controlling protein production |
| CN108601951B (zh) | 2015-12-09 | 2022-11-22 | 金港医疗(澳大利亚)私人有限公司 | 用于治疗的免疫调节组合物 |
| CA3028682A1 (en) | 2016-06-20 | 2017-12-28 | Howard Y. Chang | Circular rnas and their use in immunomodulation |
| US11285191B2 (en) | 2016-07-26 | 2022-03-29 | The Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Immunostimulatory compositions and uses therefor |
| AU2018334273B2 (en) | 2017-09-15 | 2025-04-10 | Brandeis University | Multiplex production and barcoding of genetically engineered cells |
| US10917454B1 (en) | 2019-08-01 | 2021-02-09 | Rohde & Schwarz Gmbh & Co. Kg | System and method for ATC voice quality assurance |
| WO2023070072A1 (en) | 2021-10-21 | 2023-04-27 | The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone | Retroelement-generated transcription factor decoys |
| WO2023077147A2 (en) | 2021-11-01 | 2023-05-04 | Pellis Therapeutics, Inc. | T-cell vaccines for patients with reduced humoral immunity |
| EP4426832A1 (en) | 2021-11-03 | 2024-09-11 | The J. David Gladstone Institutes, A Testamentary Trust Established under The Will of J. David Gladstone | Precise genome editing using retrons |
| WO2023141602A2 (en) | 2022-01-21 | 2023-07-27 | Renagade Therapeutics Management Inc. | Engineered retrons and methods of use |
| EP4499849A1 (en) | 2022-03-25 | 2025-02-05 | The J. David Gladstone Institutes, A Testamentary Trust Established under The Will of J. David Gladstone | Production of reverse transcribed dna (rt-dna) using a retron reverse transcriptase from exogenous rna |
| US20250223586A1 (en) | 2022-03-25 | 2025-07-10 | The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David | Methods of assessing engineered retron activity, and uses thereof |
| CA3246348A1 (en) | 2022-03-25 | 2023-09-28 | The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone | RT-DNA AND RETRONS FIDELITY GENOMIC EDITING |
| MA71557A (fr) | 2022-07-18 | 2025-05-30 | Renagade Therapeutics Management Inc. | Composants d'édition génique, systèmes et procédés d'utilisation |
| US20250243516A1 (en) | 2022-08-24 | 2025-07-31 | The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David | Dual Cut Retron Editors for Genomic Insertions and Deletions |
| WO2024044723A1 (en) | 2022-08-25 | 2024-02-29 | Renagade Therapeutics Management Inc. | Engineered retrons and methods of use |
| WO2024233791A1 (en) | 2023-05-11 | 2024-11-14 | Seelos Therapeutics, Inc. | Methods of treating neurodegenerative disorders |
| WO2025081042A1 (en) | 2023-10-12 | 2025-04-17 | Renagade Therapeutics Management Inc. | Nickase-retron template-based precision editing system and methods of use |
| WO2025155753A2 (en) | 2024-01-17 | 2025-07-24 | Renagade Therapeutics Management Inc. | Improved gene editing system, guides, and methods |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK489481A (da) * | 1980-11-10 | 1982-05-11 | Searle & Co | Plasmidvektor og frmgangsmaade til fremstilling deraf |
| US4603112A (en) * | 1981-12-24 | 1986-07-29 | Health Research, Incorporated | Modified vaccinia virus |
| AU570940B2 (en) * | 1982-11-30 | 1988-03-31 | United States of America, as represented by the Secretary, U.S. Department of Commerce, The | Process for producing poxvirus recombinants for expression offoreign genes |
| FR2563434B1 (fr) * | 1984-04-25 | 1986-07-25 | Transgene Sa | Vaccin contre la rage et procede pour sa preparation |
| WO1986000528A1 (en) * | 1984-07-05 | 1986-01-30 | Genex Corporation | Cloned gene and method for making and using the same |
| DD235669A1 (de) * | 1985-03-26 | 1986-05-14 | Akad Wissenschaften Ddr | Verfahren zur herstellung eines blv-kodierten huellproteins |
| US5032520A (en) * | 1985-03-29 | 1991-07-16 | National Research Development Corporation | DNA sequences encoding infectious bronchitis virus spike protein |
| EP0213894A3 (en) * | 1985-08-23 | 1987-10-21 | Advanced Genetics Research Institute | Defective viral particle vaccines and methods for their use |
| AU607399B2 (en) * | 1985-09-09 | 1991-03-07 | Cetus Corporation | Infectious recombinant virus vaccine for feline leukemia |
| NZ217645A (en) * | 1985-09-25 | 1991-11-26 | Oncogen | Recombinant viruses expressing lav/htlv-iii related epitopes and vaccine formulations |
| AU602875B2 (en) * | 1985-12-18 | 1990-11-01 | British Technology Group Limited | Newcastle disease virus gene clones |
| AU8075787A (en) * | 1986-09-22 | 1988-04-07 | Australian National University, The | Recombinant poxviruses |
| WO1988002022A1 (en) * | 1986-09-22 | 1988-03-24 | Commonwealth Scientific And Industrial Research Or | Recombinant poxviruses |
| EP0261940A3 (en) * | 1986-09-23 | 1989-07-05 | Applied Biotechnology, Inc. | Pseudorabies vaccines and dna vectors for recombination with pox viruses |
| EP0284416B1 (en) * | 1987-03-27 | 1995-02-22 | Nippon Zeon Co., Ltd. | Recombinant avipoxyvirus |
| DE10399032I1 (de) * | 1987-08-28 | 2004-01-29 | Health Research Inc | Rekombinante Viren. |
| GB8724885D0 (en) * | 1987-10-23 | 1987-11-25 | Binns M M | Fowlpox virus promotors |
| FR2632863B2 (fr) * | 1987-10-29 | 1990-08-31 | Transgene Sa | Virus du fowlpox recombinant et vaccins derives de ces virus |
| US5310671A (en) * | 1988-06-24 | 1994-05-10 | British Technology Group Limited | Fowlpox virus non-essential regions |
| WO1990010693A1 (en) * | 1989-03-08 | 1990-09-20 | Health Research, Inc. | Recombinant poxvirus host selection system |
| JP3895366B2 (ja) * | 1990-09-25 | 2007-03-22 | キャンタブ ファーマシューティカルズ リサーチ リミティド | ウィルス ワクチン |
-
1987
- 1987-08-24 DE DE2003199032 patent/DE10399032I1/de active Pending
- 1987-08-24 DE DE2003199031 patent/DE10399031I1/de active Pending
-
1988
- 1988-08-24 CH CH1652/89A patent/CH679933A5/de not_active IP Right Cessation
- 1988-08-24 WO PCT/US1988/002816 patent/WO1989003429A1/en not_active Ceased
- 1988-08-24 JP JP50771588A patent/JP3348156B2/ja not_active Expired - Lifetime
- 1988-08-24 CH CH1444/91A patent/CH679934A5/de not_active IP Right Cessation
- 1988-08-24 DE DE2002199049 patent/DE10299049I1/de active Pending
- 1988-08-24 NL NL8820679A patent/NL195051C/nl not_active IP Right Cessation
- 1988-08-24 KR KR1019890700753A patent/KR970011149B1/ko not_active Expired - Lifetime
- 1988-08-24 AU AU24275/88A patent/AU2427588A/en not_active Abandoned
- 1988-08-24 GB GB8908921A patent/GB2217718B/en not_active Expired - Lifetime
- 1988-08-24 DE DE3890874A patent/DE3890874C5/de not_active Expired - Lifetime
- 1988-08-24 AT AT0900788A patent/AT408549B/de not_active IP Right Cessation
- 1988-08-28 IL IL87581A patent/IL87581A0/xx not_active IP Right Cessation
- 1988-08-29 FR FR888811334A patent/FR2621487B1/fr not_active Expired - Lifetime
- 1988-08-29 IT IT8821772A patent/IT1229484B/it active
- 1988-08-29 AR AR88311787A patent/AR241939A1/es active
- 1988-08-29 BE BE8800978A patent/BE1002134A5/fr not_active IP Right Cessation
- 1988-08-29 NZ NZ225970A patent/NZ225970A/xx unknown
-
1989
- 1989-04-27 DK DK198902036A patent/DK175904B1/da active Protection Beyond IP Right Term
-
1995
- 1995-04-05 AU AU16288/95A patent/AU690210B2/en not_active Expired
-
2001
- 2001-10-09 JP JP2001311076A patent/JP2002186494A/ja active Pending
-
2002
- 2002-03-15 JP JP2002071416A patent/JP3826055B2/ja not_active Expired - Lifetime
- 2002-09-04 LU LU90951C patent/LU90951I2/fr unknown
-
2003
- 2003-07-09 NL NL300130C patent/NL300130I2/nl unknown
- 2003-09-05 LU LU91039C patent/LU91039I2/fr unknown
- 2003-11-25 NL NL300138C patent/NL300138I2/nl unknown
- 2003-11-25 NL NL300139C patent/NL300139I1/nl unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK175904B1 (da) | Rekombinant avipoxvirus, viruset til anvendelse ved fremstilling af et lægemiddel til vertebrater og anvendelse af viruset ved fremstilling af et lægemiddel til behandling af pattedyr eller fugle for en infektion med et pattedyr- eller fuglepatogen | |
| US5505941A (en) | Recombinant avipox virus and method to induce an immune response | |
| US5174993A (en) | Recombinant avipox virus and immunological use thereof | |
| EP0431668B1 (en) | Recombinant herpesvirus of turkeys and live vector vaccines derived thereof | |
| IT9020063A1 (it) | Vaccino di poxvirus ricombinante di herpesvirus | |
| JPH06505874A (ja) | 遺伝子操作したワクチン菌株 | |
| US5891442A (en) | Infectious bursal disease virus recombination poxvirus vaccine | |
| US5651972A (en) | Use of recombinant swine poxvirus as a live vaccine vector | |
| AU724172B2 (en) | Recombinant poxvirus-feline infectious peritonitis virus, compositions thereof and methods for making and using them | |
| US5641490A (en) | Infectious bursal disease virus recombinant poxvirus vaccine | |
| WO2007115385A2 (en) | Transfer plasmidic vector and recombinant canarypox virus | |
| DK175980B1 (da) | Recombinante vacciniavira og anvendelsen af samme | |
| DK176068B1 (da) | Rekombinant kanaripoxvirus og anvendelsen af samme | |
| IE912591A1 (en) | Herpesvirus-based viral vector which expresses a foot and¹mouth disease virus epitope on the surface of virus-infected¹cells and on the surface of virus particles, and vaccine¹against foot and mouth disease containing the same | |
| DK176165B1 (da) | Rekombinant fjerkræpoxvirus samt anvendelsen af samme | |
| AU761321B2 (en) | Recombinant viruses, vaccines containing them and in vitro cell cultures thereof | |
| CA1341403C (en) | Recombinant a vipox virus | |
| AU725985B2 (en) | Recombinant virus | |
| AU769221B2 (en) | Recombinant poxvirus-feline infectious peritonitis virus, compositions thereof and methods for making and using them | |
| IE882620L (en) | Recombinant avipox virus | |
| WO1999037327A1 (en) | A virus vaccine of enhanced immunogenicity against aujeszky's disease |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| CTFF | Application for supplementary protection certificate (spc) filed |
Spc suppl protection certif: CA 2005 00049 Filing date: 20051206 Expiry date: 20130824 Spc suppl protection certif: CA 2005 00050 Filing date: 20051206 Expiry date: 20130824 |
|
| CTFF | Application for supplementary protection certificate (spc) filed |
Spc suppl protection certif: CA 2005 00050 Filing date: 20051206 Expiry date: 20130824 Spc suppl protection certif: CA 2005 00049 Filing date: 20051206 Expiry date: 20130824 |
|
| PUP | Patent expired | ||
| CTFG | Supplementary protection certificate (spc) issued |
Free format text: PRODUCT NAME: REKOMBINANT CANARYPOX VIRUS, DER UDTRYKKER MINDST ET HAEMAGGLUTININ FRA INFLUENZAVIRUS Spc suppl protection certif: CA 2005 00049 Filing date: 20051206 Free format text: PRODUCT NAME: REKOMBINANT CANARYPOX VIRUS, DER UDTRYKKER ET FELV ANTIGEN Spc suppl protection certif: CA 2005 00050 Filing date: 20051206 |